Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 12/20 | 0.42 |
| ▸ | ANPEP | P15144 | 7/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18007438 | 0.92 | HCAR2 (0.38) | MMP2ANPEPHCAR2ALDH1A1ATM | |
| SCHEMBL18009458 | 0.88 | MMP2 (0.54) | MMP2ANPEPKEAP1NFE2L2HCAR2 | |
| SCHEMBL18009388 | 0.87 | PEPD (0.34) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL18009450 | 0.83 | ATM (0.47) | MMP2ANPEPKEAP1NFE2L2HCAR2 | |
| SCHEMBL18009337 | 0.82 | MMP2 (0.42) | MMP2ANPEPKEAP1NFE2L2HCAR2 | |
| SCHEMBL18009283 | 0.82 | ALDH1A1 (0.40) | MMP2ALDH1A1 | |
| SCHEMBL18009188 | 0.82 | FKBP1A (0.45) | MMP2HCAR2ALDH1A1 | |
| SCHEMBL18009463 | 0.82 | MMP2 (0.42) | MMP2ANPEPKEAP1NFE2L2HCAR2 | |
| SCHEMBL18009202 | 0.82 | MMP2 (0.42) | MMP2ANPEPKEAP1NFE2L2HCAR2 | |
| SCHEMBL18009464 | 0.81 | MMP2 (0.35) | MMP2ANPEPKEAP1NFE2L2HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016127186-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2016-08-11 | — | — | WO | disclosed |